P-Cure

Company Overview

Snapshot

Founded in January 2007 by Michael Marash, P-Cure operates with 11–50 employees and has raised a total of $36 million across 4 funding rounds from 4 investors. In June 2022, the company announced preparations to establish the world's largest production facility for proton therapy systems to meet market demand.

Business overview

P-Cure develops an imaging-based solution for cost-effective cancer treatment utilizing proton radiation. Its proprietary delivery system facilitates the use of fixed-beam technologies for various cancer indications, aiming to enhance treatment accuracy, broaden treatable conditions, and reduce procedure times. The P-Cure system is compatible with existing accelerators and treatment protocols. Its flagship product, the P-ARTIS, is a comprehensive solution for proton therapy, integrating diagnostic-quality volumetric imaging, a robotic positioning system, and real-time X-ray imaging. The company serves the healthcare industry, specifically targeting hospitals and clinics with its medical equipment and treatment solutions in the Health Tech & Life Sciences sector.

Strategic signal

In March 2022, P-Cure demonstrated that its proton therapy equipment can be installed in existing radiation therapy rooms, a significant development for the industry. This innovation signals a potential reduction in the infrastructure costs and complexities associated with adopting advanced proton therapy, making this highly effective cancer treatment more accessible to a wider range of healthcare providers and patients. For investors, this indicates a strategic move towards broader market penetration and a more scalable business model.

Company Intelligence Q&A

What is P-Cure's primary product?

P-Cure's primary product is the P-ARTIS, a comprehensive and fully integrated solution designed for treating patients with protons. It includes diagnostic-quality volumetric imaging, a robotic positioning system, and real-time X-ray imaging.

When did P-Cure last raise funding?

In February 2021, P-Cure secured a funding round from investor Popular Line Medical.

What significant regulatory milestone did P-Cure achieve in April 2020?

In April 2020, P-Cure secured CE Marking for its breakthrough image-guided positioning system, validating its technology for the European market.

What was a key development for P-Cure in July 2022?

In July 2022, a new form of proton therapy for cancer developed by P-Cure began trials in Jerusalem, marking a step forward in clinical validation.

What strategic partnership did P-Cure form in January 2014?

In January 2014, Philips Healthcare teamed with P-Cure on proton therapy, indicating a collaboration to advance the technology.